Siegfried Reich, P.H.D
2021
In 2021, Siegfried Reich, P.H.D earned a total compensation of $4M as Executive Vice President and Chief Scientific Officer at Turning Point Therapeutics, a 31% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $216,215 |
|---|---|
| Option Awards | $1,662,593 |
| Salary | $417,000 |
| Stock Awards | $1,658,418 |
| Other | $11,600 |
| Total | $3,965,826 |
PHD received $1.7M in option awards, accounting for 42% of the total pay in 2021.
PHD also received $216.2K in non-equity incentive plan, $417K in salary, $1.7M in stock awards and $11.6K in other compensation.
Rankings
In 2021, Siegfried Reich, P.H.D's compensation ranked 3,383rd out of 12,406 executives tracked by ExecPay. In other words, PHD earned more than 72.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,383 out of 12,406 | 73rd |
Division Manufacturing | 1,372 out of 5,492 | 75th |
Major group Chemicals And Allied Products | 556 out of 2,368 | 77th |
Industry group Drugs | 495 out of 2,089 | 76th |
Industry Pharmaceutical Preparations | 343 out of 1,536 | 78th |
Source: SEC filing on April 29, 2022.
PHD's colleagues
We found six more compensation records of executives who worked with Siegfried Reich, P.H.D at Turning Point Therapeutics in 2021.
2021
Athena Countouriotis
Turning Point Therapeutics
Chief Executive Officer
2021
Mohammad Hirmand
Turning Point Therapeutics
Chief Medical Officer
2021
Annette North
Turning Point Therapeutics
General Counsel
2021
Paolo Tombesi
Turning Point Therapeutics
Chief Financial Officer
2021
Yi Larson
Turning Point Therapeutics
Chief Financial Officer
2021
Brian Baker
Turning Point Therapeutics